Norethindrone: How It Works, Dosing by Life Stage, and What Women Need to Know

First, Let's Clear Up the Injection Question

Norethindrone does not come in a self-injectable form. Full stop.

If you searched for "norethindrone self-injection technique," you may be thinking of a different progestin. Depot medroxyprogesterone acetate (DMPA, brand name Depo-Provera) is the progestin contraceptive that is given by injection, and subcutaneous DMPA 104 mg/0.65 mL can be self-administered at home. Norethindrone, by contrast, is an oral tablet only. The two drugs are both progestins, but they are chemically distinct and are not interchangeable.

This article covers exactly how norethindrone and norethindrone acetate work, what the real clinical evidence says about their use in women across every life stage, and how to use them safely.

What Norethindrone Actually Is: Two Closely Related Drugs

Norethindrone and norethindrone acetate are not the same drug, even though pharmacies and patients often use the names interchangeably.

Norethindrone (base form)

The base compound is available as a 0.35 mg tablet, marketed as the progestin-only pill (POP), sometimes called the "mini-pill." FDA-approved labeling lists its single indication as contraception.

Norethindrone Acetate

Norethindrone acetate (NETA) is the acetate ester of norethindrone. It is roughly twice as potent mg-for-mg because acetylation improves oral bioavailability. NETA tablets come in 5 mg doses and carry FDA approval for endometriosis, secondary amenorrhea, abnormal uterine bleeding, and as the progestin component of combination hormone therapy.

Why the Potency Difference Matters for Women

Because NETA is more potent per milligram, dosing errors between the two forms carry real clinical consequence. A woman taking NETA for endometriosis at 10 mg daily is receiving a progestogenic load that would be the equivalent of roughly 20 mg of the base compound. That level of progestin exposure can suppress the hypothalamic-pituitary-ovarian axis substantially, which matters for fertility planning.

How Norethindrone Works: The Mechanism in Female Physiology

Norethindrone binds primarily to the progesterone receptor (PR), but it also has partial affinity for the androgen receptor (AR) and, at high doses, for the glucocorticoid receptor. This receptor profile drives most of its clinical effects and most of its side effects in women.

Uterine Effects

In the endometrium, norethindrone converts proliferative endometrium (estrogen-driven growth) into secretory and then atrophic endometrium. This is the mechanism behind its effectiveness for heavy menstrual bleeding (HMB). A 2013 Cochrane review found that oral progestins administered in the luteal phase reduced menstrual blood loss, though continuous long-cycle dosing produced greater reductions than short-cycle regimens. The same review noted that the levonorgestrel intrauterine system outperformed oral progestins for HMB, a clinically useful comparison your provider should walk through with you.

Ovarian Suppression

At the 0.35 mg contraceptive dose, norethindrone does not reliably suppress ovulation in all cycles. Studies show it inhibits ovulation in approximately 50 to 60 percent of cycles, making its contraceptive effect heavily dependent on cervical mucus thickening and endometrial thinning. This is why the progestin-only pill has a strict 3-hour daily intake window: missing that window reduces mucus-mediated protection before the next dose restores it.

At the 5 to 15 mg doses used for endometriosis, ovulation is suppressed much more reliably. The deeper hypothalamic effect at higher doses creates a pseudopregnancy or pseudomenopause state that reduces ectopic endometrial tissue activity.

Androgenic Activity and Its Female Relevance

Norethindrone's partial androgen receptor agonism is clinically meaningful for women with androgen-sensitive conditions. In women with PCOS who already have elevated androgens, adding a progestin with androgenic activity may worsen acne or hirsutism compared to a non-androgenic progestin like drospirenone or micronized progesterone. This is not a theoretical concern: progestin androgen receptor activity is a recognized source of differential side effects in women, and your provider should factor your androgen status into progestin selection.

Conversely, at the doses used in combination oral contraceptives containing norethindrone acetate, the net androgenicity is usually low because co-administered estrogen increases sex hormone-binding globulin (SHBG), which binds free androgens. The androgenic concern is most relevant when norethindrone is used as monotherapy, particularly in perimenopausal women on progestin-only hormone therapy.

Dosing Across Female Life Stages

The right dose of norethindrone depends heavily on where you are in your reproductive life. No single dose fits every stage.

Reproductive Years: Contraception

The progestin-only pill (0.35 mg norethindrone daily) suits women who cannot use estrogen-containing contraceptives: those with migraine with aura, a history of venous thromboembolism, hypertension, or who are breastfeeding. ACOG Practice Bulletin on contraception categorizes progestin-only pills as generally safe where combined pills are contraindicated.

The 3-hour window is non-negotiable. Take it at the same time every day. If you are more than 3 hours late, use backup contraception for 48 hours.

Reproductive Years: Heavy Menstrual Bleeding

For HMB not caused by structural pathology, norethindrone acetate 5 mg twice or three times daily from cycle days 5 through 26 is a commonly used regimen. The Cochrane review by Lethaby et al. (2008, updated 2019) confirmed that this schedule reduces menstrual blood loss significantly compared to placebo, though it also noted higher discontinuation rates due to side effects compared to the levonorgestrel IUD.

Reproductive Years: Endometriosis

NETA is one of the first-line medical treatments for endometriosis-associated pain. Starting doses are typically 5 mg daily, increasing by 2.5 mg every two weeks as tolerated, up to 15 mg daily. The goal is amenorrhea. Breakthrough bleeding during titration is managed by adding small amounts of estrogen transiently, a strategy sometimes called "add-back therapy."

Expect 3 to 6 months before maximum pain relief. Women with endometriosis who also want to conceive cannot stay on NETA long-term: ovarian suppression is reversible, but treatment must stop before attempting conception.

PCOS

Women with PCOS who have irregular cycles and unopposed estrogen from anovulation need progestin to protect the endometrium from hyperplasia. Norethindrone acetate 5 mg for 10 to 14 days per cycle can induce a withdrawal bleed and reduce hyperplasia risk. However, because of its androgenic activity, it may not be the best progestin choice for women with PCOS who already have elevated testosterone or significant acne. Micronized progesterone or a non-androgenic progestin may suit those women better.

Perimenopause

During perimenopause, estrogen fluctuates and progesterone production from ovulation becomes erratic. Women who still have a uterus and are using estrogen therapy need a progestin to protect the endometrium. NETA 0.1 mg combined with estradiol (as in several combination patches) or NETA 0.35 to 5 mg oral doses are used in this context.

A practical framework for progestin selection in perimenopause: consider three variables together: (1) androgenic sensitivity (acne, hirsutism, PCOS history), (2) VTE risk profile, and (3) mood tolerance for synthetic progestins. Women with any two of these three concerns should have a direct conversation with their provider about micronized progesterone or a lower-androgenicity option before defaulting to norethindrone.

Postmenopause: Hormone Therapy Add-Back

In postmenopausal women on systemic estrogen therapy, a progestin is required to prevent endometrial hyperplasia and cancer if the uterus is intact. NETA at doses as low as 0.1 mg daily (in combination patches like Combipatch) provides adequate endometrial protection. The PEPI trial established that unopposed estrogen in women with a uterus significantly increases endometrial hyperplasia risk, reinforcing why the progestin component is non-optional in that population.

Women post-hysterectomy do not need a progestin and should not take one unnecessarily given the side-effect burden.

Sex-Specific Pharmacokinetics: How Your Body Handles Norethindrone Differently

Women metabolize oral progestins through cytochrome P450 enzymes, principally CYP3A4. Body composition, liver function, and hormonal status all modulate exposure. Compared to men (the population that historically shaped dosing assumptions), women tend to have higher adipose mass, which can extend the effective half-life of lipophilic drugs like norethindrone. Norethindrone has a reported half-life of approximately 5 to 14 hours, but individual variation in women based on cycle phase, body composition, and age is real and understudied.

Drugs that induce CYP3A4 (rifampin, certain antiepileptics including phenytoin and carbamazepine, and St. John's Wort) reduce norethindrone plasma levels and can cause contraceptive failure. This is a named concern in ACOG guidance on drug interactions with hormonal contraceptives.

Women with hepatic impairment should not use norethindrone: it is hepatically metabolized and carries a labeled contraindication for liver disease.

Evidence Gaps: What We Don't Know About Norethindrone in Women

Women have been systematically under-represented in pharmacokinetic studies of progestins. Most PK data come from studies in reproductive-age women, with far less data on how menopause, surgical oophorectomy, or aging changes norethindrone metabolism. The evidence on optimal progestin type and dose for perimenopausal women specifically is extrapolated largely from postmenopausal HRT trials rather than from perimenopausal cohorts. That gap is real, and any claim of a definitively "optimal" progestin for perimenopause should be treated skeptically.

Long-term safety data on high-dose NETA (10 to 15 mg/day for endometriosis) in women across multiple years is also limited. Most endometriosis trials run 6 to 12 months. What happens to bone density, lipid profiles, and androgenic side effects over 2 to 3 years at those doses is not well characterized in randomized controlled data.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy: Contraindicated

Norethindrone and norethindrone acetate are contraindicated in known or suspected pregnancy. FDA labeling places norethindrone in the former Pregnancy Category X based on animal data showing masculinization of female fetuses at high doses, and on epidemiological signal for genital abnormalities with first-trimester progestin exposure.

The absolute risk from inadvertent first-trimester exposure is considered low but is not zero. If you become pregnant while taking norethindrone, stop the drug immediately and contact your provider. Do not use norethindrone in any dose as a pregnancy test or to "support" a pregnancy: there is no evidence it prevents miscarriage and it carries fetal risk.

If you are prescribed norethindrone acetate for endometriosis or HMB and are sexually active with the possibility of pregnancy, you need a reliable contraceptive method in addition to the NETA dose, unless the NETA dose itself is your contraceptive.

Trying to Conceive

Stop norethindrone before attempting conception. Ovulation typically resumes within 1 to 3 months after stopping the progestin-only pill. Return to fertility after stopping high-dose NETA for endometriosis may take longer given deeper ovarian suppression, though most women ovulate within 3 to 6 months of stopping.

Lactation

Norethindrone transfers into breast milk in small amounts. CDC reproductive health guidance categorizes progestin-only pills as generally safe for breastfeeding women (MEC category 1 or 2 depending on timing postpartum), with no documented harm to infant growth or development at contraceptive doses. The progestin-only pill is a preferred contraceptive option for lactating women because it does not reduce milk supply, unlike estrogen-containing methods.

At higher NETA doses (5 mg and above for HMB or endometriosis), lactation safety data are sparse. High-dose use is generally avoided during breastfeeding until more data are available.

Who This Is Right For, and Who Should Look at Other Options

Women Who May Benefit from Norethindrone

• Women with heavy menstrual bleeding who need a non-surgical, oral option before considering the levonorgestrel IUD or endometrial ablation
• Women with endometriosis-associated pelvic pain who have not responded to NSAIDs or combined oral contraceptives
• Women who cannot take estrogen (migraine with aura, VTE history, uncontrolled hypertension) and need contraception
• Breastfeeding women who need contraception
• Perimenopausal and postmenopausal women who need progestin protection while using systemic estrogen therapy

Women Who Should Consider a Different Progestin

• Women with PCOS and significant androgenic symptoms (acne, hirsutism): norethindrone's partial androgenic activity may worsen these symptoms
• Women with mood sensitivity to synthetic progestins: micronized progesterone (Prometrium) has a better documented mood profile in some studies
• Women with a personal history of hormone-receptor-positive breast cancer: this is a complex shared-decision conversation; no progestin is categorically safe in that setting, and ACOG guidance recommends individualized risk-benefit discussion
• Women with active liver disease or a history of hepatic adenoma: hepatic contraindications apply to all oral progestins

Common Side Effects and What the Evidence Says About Managing Them

Norethindrone's side-effect profile in women is dominated by four categories: bleeding irregularity, mood changes, androgenic effects, and metabolic changes.

Irregular Bleeding

Irregular, unpredictable bleeding is the most common reason women stop the progestin-only pill. Studies report unscheduled bleeding in up to 40 percent of users in the first 3 months. For most women this improves by month 3 to 6. Tracking your cycle with an app during the first 3 months helps both you and your provider distinguish adaptation from a pattern that warrants a change.

Mood Effects

Synthetic progestins have documented effects on mood in some women. A large Danish cohort study published in JAMA Psychiatry found that hormonal contraception use was associated with increased risk of first depression diagnosis, with progestin-only methods showing an association comparable to combined methods in certain subgroups. The absolute risk increase was small but real. If you have a history of depression or premenstrual dysphoric disorder, flag this before starting norethindrone.

Androgenic Effects

Acne, oily skin, and mild hirsutism can occur, particularly at higher doses. These effects are more pronounced in women who already have androgen excess. Choosing a lower-androgenicity progestin is preferable in that population.

Lipid and Metabolic Effects

Norethindrone modestly reduces HDL cholesterol and may increase LDL at higher doses, reflecting its androgenic activity. Effects on lipid profiles from progestin use are well-documented and are worth monitoring in women with cardiovascular risk factors or diabetes.

Drug Interactions Every Woman Should Know

• CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort): reduce norethindrone levels, risk of contraceptive failure or reduced therapeutic effect. Use backup contraception or switch to a copper IUD.
• HIV antiretrovirals (some protease inhibitors, non-nucleoside reverse transcriptase inhibitors): complex bidirectional interactions; CDC MEC guidance should be consulted for specific agents.
• Lamotrigine: norethindrone-containing pills can reduce lamotrigine levels, potentially destabilizing seizure control. Neurologist involvement is important.

Frequently Asked Questions